Blogger

Groundbreaking Gene Therapy Study Gets The Go-Ahead By The FDA

Calimmune, a small biotechnology company, is  giving people a low dose chemo agent (as conditioning) and then infusing them with stem cells  that have been modified to inhibit the CCR5 receptor and to contain their own built-in HIV fusion inhibitor peptide, thereby blocking two sites that are essential for HIV infection.   The study is …

Groundbreaking Gene Therapy Study Gets The Go-Ahead By The FDA Read More »

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance

We have repeatedly heard the following statements about multi-drug resistant HIV (MDR-HIV) patients in a host of meetings on treatment access and HIV research: “These patients no longer exist – they’re either dead or have responded to the latest ARVs”; “Only patients who do not adhere to their HIV regimens have MDR-HIV”; and “Our clinic cannot provide expanded access programs (EAPs) due …

WORLD AIDS DAY: Time to Help Victims of HIV Drug Studies and Resistance Read More »

HIV, Active HCV, Low Income Tied to Shorter Telomeres, a Cellular Aging Marker

From Natap.org HIV, Active HCV, Low Income Tied to Shorter Telomeres, a Cellular Aging Marker3rd International Workshop on HIV and Aging, November 5-6, 2012, Baltimore Mark Mascolini HIV infection, active HCV infection, and income below $15,000 a year independently predicted shorter telomere length in a study of 229 HIV-positive people and 166 HIV-negative people in …

HIV, Active HCV, Low Income Tied to Shorter Telomeres, a Cellular Aging Marker Read More »

SIGN PETITION: Gilead Sciences: Please collaborate with Bristol Myers for the Cure for Hepatitis C NOW!

Gilead Sciences: Please collaborate with Bristol Myers for the Cure for Hepatitis C NOW! The most effective new therapy ever discovered for the treatment of hepatitis C will never see the light of day unless we are able to convince big pharma giant Gilead Sciences to move forward at once with this development. This treatment combines Bristol-Myers Squibb drug daclatasvir and …

SIGN PETITION: Gilead Sciences: Please collaborate with Bristol Myers for the Cure for Hepatitis C NOW! Read More »

Of the 1.1 million Americans living with HIV, only 25 percent are virally suppressed.

 Of the 1.1 million Americans living with HIV, only 25 percent are virally suppressed. This is worrisome data that reflects how the world’s biggest super power still has problems getting HIV infected people treated even with access to more than 24 HIV medications and federally funded programs https://www.thebody.com/content/69009/hiv-in-the-united-states-the-stages-of-care.html?ic=700100

Novel Cell and Gene Therapies for HIV

Although the development of cell-based and gene transfer therapies has been slow, progress in a number of areas is evident. Advances in the fields of gene-targeting strategies, T-cell-based approaches, and HSCs have been encouraging, and a series of ongoing and planned trials to establish proof of concept for strategies that could lead to successful cell …

Novel Cell and Gene Therapies for HIV Read More »

Johns Hopkins study suggests the commonly prescribed anti-retroviral drug efavirenz attacks brain cells

Popular HIV drug may cause memory declines Johns Hopkins study suggests the commonly prescribed anti-retroviral drug efavirenz attacks brain cells The way the body metabolizes a commonly prescribed anti-retroviral drug that is used long term by patients infected with HIV may contribute to cognitive impairment by damaging nerve cells, a new Johns Hopkins research suggests. …

Johns Hopkins study suggests the commonly prescribed anti-retroviral drug efavirenz attacks brain cells Read More »